{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T18:49:17Z","timestamp":1775933357741,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2016,9,3]],"date-time":"2016-09-03T00:00:00Z","timestamp":1472860800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment Programme","doi-asserted-by":"publisher","award":["14\/206\/01"],"award-info":[{"award-number":["14\/206\/01"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1007\/s40273-016-0447-3","type":"journal-article","created":{"date-parts":[[2016,9,3]],"date-time":"2016-09-03T04:21:34Z","timestamp":1472876494000},"page":"203-213","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["A Review of Ruxolitinib for the Treatment of Myelofibrosis: A Critique of the Evidence"],"prefix":"10.1007","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8666-8110","authenticated-orcid":false,"given":"Ros","family":"Wade","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Hodgson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mousumi","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Harden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nerys","family":"Woolacott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,9,3]]},"reference":[{"key":"447_CR1","volume-title":"Guide to the single technology appraisal (STA) process","author":"National Institute for Health and Clinical Excellence (NICE)","year":"2006","unstructured":"National Institute for Health and Clinical Excellence (NICE). Guide to the single technology appraisal (STA) process. London: NICE; 2006."},{"issue":"10","key":"447_CR2","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s40273-013-0083-0","volume":"31","author":"R Wade","year":"2013","unstructured":"Wade R, Rose M, Neilson AR, Stirk L, Rodriguez-Lopez R, Bowen D, et al. Ruxolitinib for the treatment of myelofibrosis: a NICE single technology appraisal. Pharmacoeconomics. 2013;31(10):841\u201352.","journal-title":"Pharmacoeconomics."},{"key":"447_CR3","unstructured":"National Institute for Health and Care Excellence (NICE). Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis (TA386). 2016. https:\/\/www.nice.org.uk\/guidance\/ta386 . Accessed 5 Apr 2016."},{"key":"447_CR4","unstructured":"Novartis. Single technology appraisal. Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis (review of TA289). Company evidence submission. Novartis; 2015. https:\/\/www.nice.org.uk\/guidance\/TA386\/documents\/committee-papers-2 . Accessed 5 May 2016."},{"issue":"13","key":"447_CR5","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","volume":"113","author":"F Cervantes","year":"2009","unstructured":"Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113(13):2895\u2013901.","journal-title":"Blood"},{"issue":"9","key":"447_CR6","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","volume":"115","author":"F Passamonti","year":"2010","unstructured":"Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Pereira A, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010;115(9):1703\u20138.","journal-title":"Blood"},{"issue":"4","key":"447_CR7","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1365-2141.2012.09179.x","volume":"158","author":"JT Reilly","year":"2012","unstructured":"Reilly JT, McMullin MF, Beer PA, Butt N, Conneally E, Duncombe A, et al. Guideline for the diagnosis and management of myelofibrosis. Br J Haematol. 2012;158(4):453\u201371.","journal-title":"Br J Haematol"},{"issue":"3","key":"447_CR8","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/bjh.12985","volume":"167","author":"JT Reilly","year":"2014","unstructured":"Reilly JT, McMullin MF, Beer PA, Butt N, Conneally E, Duncombe AS, et al. Use of JAK inhibitors in the management of myelofibrosis: a revision of the BCSH guidelines for investigation and management of myelofibrosis 2012. Br J Haematol. 2014;167(3):418\u201320.","journal-title":"Br J Haematol"},{"key":"447_CR9","unstructured":"National Institute for Health and Care Excellence. NICE TA289 and ruxolitinib final appraisal determination document. 2013. Ruxolitinib for disease-related splenomegaly or symptoms in adults with myelofibrosis. 2013. https:\/\/www.nice.org.uk\/guidance\/ta289\/documents\/myelofibrosis-splenomegaly-symptoms-ruxolitinib-final-appraisal-determination-document2 . Accessed 20 Feb 2014."},{"key":"447_CR10","volume-title":"Ruxolitinib for disease-related splenomegaly or symptoms in adults with myelofibrosis (review of TA289): a single technology appraisal","author":"R Hodgson","year":"2015","unstructured":"Hodgson R, Wade R, Biswas M, Harden M, Woolacott N. Ruxolitinib for disease-related splenomegaly or symptoms in adults with myelofibrosis (review of TA289): a single technology appraisal. York: CRD and CHE Technology Assessment Group; 2015."},{"issue":"9","key":"447_CR11","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","volume":"366","author":"C Harrison","year":"2012","unstructured":"Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366(9):787\u201398.","journal-title":"N Engl J Med"},{"issue":"9","key":"447_CR12","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","volume":"366","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9):799\u2013807.","journal-title":"N Engl J Med"},{"key":"447_CR13","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1182\/blood-2013-02-485888","volume":"122","author":"F Cervantes","year":"2013","unstructured":"Cervantes F, Vannucchi AM, Kiladjian J-J, Al-Ali HK, Sirulnik A, Stalbovskaya V, et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood. 2013;122:4047\u201353.","journal-title":"Blood"},{"issue":"suppl 1","key":"447_CR14","first-page":"126","volume":"99","author":"C Harrison","year":"2014","unstructured":"Harrison C, Niederwieser D, Vannucchi A, Kiladjian JJ, Barbui T, Gisslinger H, et al. Results from a 3.5-year update of COMFORT-II, a phase 3 study comparing ruxolitinib (RUX) with best available therapy (BAT) for the treatment of myelofibrosis. Haematologica. 2014;99(suppl 1):126.","journal-title":"Haematologica."},{"key":"447_CR15","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.3324\/haematol.2013.092155","volume":"98","author":"S Verstovsek","year":"2013","unstructured":"Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica. 2013;98:1865\u201371.","journal-title":"Haematologica"},{"key":"447_CR16","doi-asserted-by":"crossref","first-page":"479","DOI":"10.3324\/haematol.2014.115840","volume":"100","author":"S Verstovsek","year":"2015","unstructured":"Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, et al. Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I. Haematologica. 2015;100:479\u201388.","journal-title":"Haematologica"},{"key":"447_CR17","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1182\/blood-2013-12-544411","volume":"123","author":"F Passamonti","year":"2014","unstructured":"Passamonti F, Maffioli M, Cervantes F, Vannucchi AM, Morra E, Barbui T, et al. Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts. Blood. 2014;123:1833\u20135.","journal-title":"Blood"},{"issue":"1","key":"447_CR18","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/bjh.13379","volume":"170","author":"AJ Mead","year":"2015","unstructured":"Mead AJ, Milojkovic D, Knapper S, Garg M, Chacko J, Farquharson M, et al. Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST trial. Br J Haematol. 2015;170(1):29\u201339.","journal-title":"Br J Haematol"},{"issue":"21","key":"447_CR19","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1182\/blood.V124.21.3197.3197","volume":"124","author":"B Martino","year":"2014","unstructured":"Martino B, le Coutre P, Griesshammer M, Illmer T, Schlag R, Waller CF, et al. Safety and efficacy of Ruxolitinib in an open-label, multicenter, single-arm, expanded-access study in patients with myelofibrosis (MF): an 1144-patient update. Blood. 2014;124(21):3197.","journal-title":"Blood"},{"issue":"1","key":"447_CR20","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/1756-8722-6-81","volume":"6","author":"M Talpaz","year":"2013","unstructured":"Talpaz M, Paquette R, Afrin L, Hamburg SI, Prchal JT, Jamieson K, et al. Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts. J Hematol Oncol. 2013;6(1):81.","journal-title":"J Hematol Oncol."},{"issue":"21","key":"447_CR21","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1182\/blood.V120.21.177.177","volume":"120","author":"CN Harrison","year":"2012","unstructured":"Harrison CN, Gisslinger H, Miller CB, Kiladjian J, Atienza E, Stalbovskaya V, et al. Expand: a phase 1b, open-label, dose-finding study of ruxolitinib in patients with myelofibrosis and baseline platelet counts between 50\u00a0\u00d7\u00a0109\/L and 99\u00a0\u00d7\u00a0109\/L [abstract]. Blood. 2012;120(21):177.","journal-title":"Blood"},{"issue":"21","key":"447_CR22","doi-asserted-by":"crossref","first-page":"4255","DOI":"10.1182\/blood.V120.21.4255.4255","volume":"120","author":"K Ouagari El","year":"2012","unstructured":"El Ouagari K, Knight CJ, Mendelson ET. Cost-effectiveness of ruxolitinib versus best-available therapy for medical treatment of myelofibrosis: Canadian societal perspective [abstract]. Blood. 2012;120(21):4255.","journal-title":"Blood"},{"issue":"6","key":"447_CR23","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.jval.2015.07.004","volume":"18","author":"C Mukuria","year":"2015","unstructured":"Mukuria C, Rowen D, Brazier JE, Young TA, Nafees B. Deriving a preference-based measure for myelofibrosis from the EORTC QLQ-C30 and the MF-SAF. Value Health. 2015;18(6):846\u201355.","journal-title":"Value Health."},{"issue":"8","key":"447_CR24","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1182\/blood-2013-03-488098","volume":"122","author":"A Tefferi","year":"2013","unstructured":"Tefferi A, Cervantes F, Mesa R, Passamonti F, Verstovsek S, Vannucchi AM, et al. Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood. 2013;122(8):1395\u20138.","journal-title":"Blood"},{"key":"447_CR25","unstructured":"National Institute for Health and Care Excellence (NICE). Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis (TA386). Final Appraisal Determination (FAD). 2016. https:\/\/www.nice.org.uk\/guidance\/TA386\/documents\/final-appraisal-determination-document . Accessed 5 Apr 2016."}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-016-0447-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40273-016-0447-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-016-0447-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-016-0447-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T19:19:27Z","timestamp":1601061567000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40273-016-0447-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,3]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["447"],"URL":"https:\/\/doi.org\/10.1007\/s40273-016-0447-3","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,3]]}}}